AR052541A1 - Vacunas de glicoconjugados que contiene peptidoglicina - Google Patents

Vacunas de glicoconjugados que contiene peptidoglicina

Info

Publication number
AR052541A1
AR052541A1 ARP050105201A ARP050105201A AR052541A1 AR 052541 A1 AR052541 A1 AR 052541A1 AR P050105201 A ARP050105201 A AR P050105201A AR P050105201 A ARP050105201 A AR P050105201A AR 052541 A1 AR052541 A1 AR 052541A1
Authority
AR
Argentina
Prior art keywords
capsular polysaccharide
vaccine
peptidoglycin
glicoconjugated
vaccines containing
Prior art date
Application number
ARP050105201A
Other languages
English (en)
Original Assignee
Nabi Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabi Biopharmaceuticals filed Critical Nabi Biopharmaceuticals
Publication of AR052541A1 publication Critical patent/AR052541A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Vacunas para tratar infecciones bacterianas, que comprenden un inmunogeno glicoconjugado que consiste en al menos un polisacárido capsular conjugado con una proteína portadora, de modo tal que el polisacárido capsular contiene una cantidad de péptidoglicano eficaz para mejorar las propiedades de la vacuna. Reivindicacion 2: La vacuna de la reivindicacion 1, donde el inmunogeno glicoconjugado comprende un polisacárido capsular expresado por Staphylococcus. Reivindicacion 5: La vacuna de la reivindicacion 1, donde la proteína portadora se selecciona del grupo que consiste en la exotoxina A de Pseudomonas, el toxoide del tétanos y la difteria, la alfa hemolisina, y la leucocidina de Panton-Valentine.
ARP050105201A 2004-12-14 2005-12-12 Vacunas de glicoconjugados que contiene peptidoglicina AR052541A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/010,563 US20060134141A1 (en) 2004-12-14 2004-12-14 Glycoconjugate vaccines containing peptidoglycan

Publications (1)

Publication Number Publication Date
AR052541A1 true AR052541A1 (es) 2007-03-21

Family

ID=36588365

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105201A AR052541A1 (es) 2004-12-14 2005-12-12 Vacunas de glicoconjugados que contiene peptidoglicina

Country Status (12)

Country Link
US (1) US20060134141A1 (es)
EP (1) EP1846025A2 (es)
JP (1) JP2008523142A (es)
KR (1) KR20070090011A (es)
CN (1) CN101132810A (es)
AR (1) AR052541A1 (es)
AU (1) AU2005316864B2 (es)
CA (1) CA2591442A1 (es)
MX (1) MX2007007090A (es)
NZ (1) NZ556533A (es)
TW (1) TW200633719A (es)
WO (1) WO2006065553A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020092987A1 (en) * 1998-09-05 2002-07-18 Taehee Cho Photo detect device using quantum dots and materialization method thereof
WO2004043405A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
WO2004050846A2 (en) * 2002-12-02 2004-06-17 Biosynexus Incorporated Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines
GB0314372D0 (en) * 2003-06-20 2003-07-23 Dana Corp Bearings
MX2007008358A (es) * 2005-01-10 2007-09-06 Nabi Biopharmaceuticals Metodo para tratar la infeccion con staphylococcus aureus.
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
JP5096326B2 (ja) * 2005-06-13 2012-12-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ブドウ球菌感染を治療および予防するためのＰａｎｔｏｎ−Ｖａｌｅｎｔｉｎｅロイコシジンの使用
NZ570805A (en) * 2006-03-30 2011-10-28 Glaxosmithkline Biolog Sa Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
TW200744632A (en) * 2006-06-12 2007-12-16 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
US8840906B2 (en) * 2007-08-31 2014-09-23 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung disease and conditions
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
KR101785373B1 (ko) 2008-07-21 2017-10-16 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
US8758765B2 (en) * 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
PL2414387T3 (pl) 2009-04-03 2016-06-30 Univ Chicago Kompozycje i sposoby związane z wariantami białka A (SpA)
EP3461496B1 (en) 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
PE20110023A1 (es) 2009-06-22 2011-01-31 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus
US8974799B2 (en) 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
DK2493498T3 (en) 2009-10-30 2017-05-08 Glaxosmithkline Biologicals Sa Purification of Staphylococcus aureus type 5 and type 8 capsule saccharides
KR20130093084A (ko) 2010-07-02 2013-08-21 더 유니버시티 오브 시카고 단백질 Ａ(ＳｐＡ) 변이체와 관련된 조성물 및 방법
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
CA3000591A1 (en) 2015-10-13 2017-04-20 Sanofi Pasteur Immunogenic compositions against s. aureus
AR109621A1 (es) * 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
US20200377620A1 (en) * 2017-12-19 2020-12-03 The Governors Of The University Of Alberta Clostridium perfringens surface glycans and uses thereof
WO2023133143A1 (en) * 2022-01-05 2023-07-13 Bluewillow Biologics, Inc. Intranasal polysaccharide conjugate nanoemulsion vaccines and methods of using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2321896A1 (fr) * 1975-08-29 1977-03-25 Anvar Agents adjuvants immunologiques actifs en solution aqueuse
WO1993009811A1 (en) * 1991-11-22 1993-05-27 Univax Biologics, Inc. TYPE I AND TYPE II SURFACE ANTIGENS ASSOCIATED WITH $i(STAPHYLOCOCCUS EPIDERMIDIS)
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
JPH11255664A (ja) * 1998-03-10 1999-09-21 Ajinomoto Co Inc 経口投与用免疫増強剤
ES2321892T3 (es) * 1998-09-14 2009-06-12 Nabi Biopharmaceuticals Composiciones de beta-glucanos e inmunoglobulinas especificas.
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US20030113350A1 (en) * 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations

Also Published As

Publication number Publication date
WO2006065553A2 (en) 2006-06-22
TW200633719A (en) 2006-10-01
EP1846025A2 (en) 2007-10-24
US20060134141A1 (en) 2006-06-22
AU2005316864B2 (en) 2010-10-28
CA2591442A1 (en) 2006-06-22
CN101132810A (zh) 2008-02-27
MX2007007090A (es) 2008-02-21
KR20070090011A (ko) 2007-09-04
AU2005316864A1 (en) 2006-06-22
NZ556533A (en) 2009-05-31
WO2006065553A3 (en) 2006-10-05
JP2008523142A (ja) 2008-07-03

Similar Documents

Publication Publication Date Title
AR052541A1 (es) Vacunas de glicoconjugados que contiene peptidoglicina
PE20071058A1 (es) Vacuna de streptococcus pneumoniae
NZ595178A (en) Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
BRPI0408167A (pt) conjugados de polissacarìdeo-proteìna veìculo adesina da superfìcie estafilocócica para imunização contra infecções nosocomiais
AR125327A2 (es) Composiciones de neisseria meningitidis y métodos de las mismas
AR100859A1 (es) Polisacáridos y sus usos
PE20110065A1 (es) Composiciones y metodos para preparar composiciones inmunogenicas de conjugado de polisacarido capsular de staphylococcus aureus serotipos 5 y 8
BRPI0515520A (pt) composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica
AR092897A1 (es) Composiciones inmunogenicas
BR9808772A (pt) Composição de vacina multivalente com carreadora misturada
PE11298A1 (es) Vacunas
EA201391788A1 (ru) Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
GB201101665D0 (en) Immunogenic compositions
EP1455817A4 (en) EXOPOLYSACCHARIDE OF GOLD STAPHYLOCOCCUS AND PROCESS
BRPI0408085A (pt) composição e método para o tratamento e prevenção de infecções entéricas bacterianas
AR055580A1 (es) Uso de leucocidina de panton valentine para el tratamiento y prevencion de infecciones por estafilococos
EA202091690A1 (ru) Иммуногенная композиция, содержащая стафилококковые антигены
AR068419A1 (es) Cepas de mycoplasma atenuadas vivas
BRPI0410341A (pt) conjugados de polissacarìdeo-proteìna derivatizados de meningococos multivalente e vacina
MX2023013434A (es) Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
AR001618A1 (es) Adyuvante de saponina del arbol quillajay y formulacion de vacuna que contiene el mismo
WO2018083490A3 (en) Capped oligosaccharides comprising seven or more units of 4,6-dideoxy-4-acylamido-alpha-pyranose and conjugates thereof as vaccines against infections caused by brucella organisms
BRPI0516372A (pt) conjugados de polissacarìdeo-proteìna derivatizados meningocócicos multivalentes e vacina
CL2021002992A1 (es) Métodos y composiciones que comprenden variantes de la proteína a de estafilococos (spa)
MX2021015155A (es) Polisacaridos de ramnosa.

Legal Events

Date Code Title Description
FB Suspension of granting procedure